MRVL Stock Overview
A life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Marvel Biosciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.17 |
| 52 Week High | CA$0.19 |
| 52 Week Low | CA$0.06 |
| Beta | 0.48 |
| 11 Month Change | 65.00% |
| 3 Month Change | 37.50% |
| 1 Year Change | 73.68% |
| 33 Year Change | -28.26% |
| 5 Year Change | n/a |
| Change since IPO | -57.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRVL | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 3.1% | -2.9% | 2.1% |
| 1Y | 73.7% | -8.6% | 23.4% |
Return vs Industry: MRVL exceeded the Canadian Biotechs industry which returned -1.9% over the past year.
Return vs Market: MRVL exceeded the Canadian Market which returned 23.1% over the past year.
Price Volatility
| MRVL volatility | |
|---|---|
| MRVL Average Weekly Movement | 16.5% |
| Biotechs Industry Average Movement | 11.8% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: MRVL's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: MRVL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Rod Matheson | marvelbiotechnology.com |
Marvel Biosciences Corp., a life sciences company, primarily focuses on the discovery and the development of synthetic derivative compound of a known proven drug. The company’s lead compound MB-204, a novel fluorinated derivative of Istradefylline, which is a clinically approved adenosine A2a receptor antagonist used for the treatment of Parkinson’s disease. It targets diseases, such as depression, Alzheimer’s disease, and liver fibrosis due to non-alcoholic steatohepatitis.
Marvel Biosciences Corp. Fundamentals Summary
| MRVL fundamental statistics | |
|---|---|
| Market cap | CA$7.61m |
| Earnings (TTM) | -CA$2.10m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs MRVL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRVL income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.10m |
| Earnings | -CA$2.10m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.047 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -54.4% |
How did MRVL perform over the long term?
See historical performance and comparison